The Progress, Achievement and Challenge of Immunotherapy in Colorectal Cancer

Lin Yi Z and Yu Qiang L

Department of Gastrointestinal Surgery, Xiangya Hospital, Central South University, China

^*Correspondance to: Zheng Lin Yi 

 PDF  Full Text Review Article | Open Access

Abstract:

Colorectal Cancer (CRC) is currently one of the most common malignant tumors worldwide, and its incidence and mortality are increasing year by year. In 2023, colorectal cancer has become the second most common cancer in China. Fortunately, the advent of immunotherapy has changed the therapeutic prospects of various solid tumors and has gradually become the main treatment for metastatic or recurrent solid tumors in recent years, including non-small cell lung cancer, liver cancer and malignant melanoma. Among them, encouraging progress has been made in the use of Immune Checkpoint Inhibitor (ICI)-based immunotherapy in patients with Colorectal Cancer (CRC), and various immunotherapeutic agents such as pembrolizumab, nivolumab, and ipilimumab have been approved for the treatment of advanced colorectal cancer. In this review, we summarize the past advances in immunotherapy in colorectal cancer and briefly introduce biomarkers that may play a key role in efficacy prediction in colorectal cancer immunotherapy.

Keywords:

Colorectal cancer; Immunotherapy; Immune checkpoint inhibitor

Cite the Article:

Lin Yi Z, Yu Qiang L. The Progress, Achievement and Challenge of Immunotherapy in Colorectal Cancer. Clin Oncol. 2024;9:2048..